Prostate cancer kills approximately 30,000 men in the US every year. For many, the disease is highly treatable and can be controlled with medical therapy for many years. An understanding of the factors that drive prostate cancer to become potentially lethal has led to a variety of new treatments that go far beyond standard chemotherapy approaches to cancer. Patients with advanced prostate cancer are currently treated with combinations and sequences of immunotherapies, hormonal approaches and chemotherapy. UCSF oncologist Dr. Charles J. Ryan covers the clinical and biological factors that drive treatment choice and sequence by physicians, and highlights how prostate cancer therapies are emblematic of the progress that is being made against cancer in general. Further, he addresses the challenges faced by patients and doctors and the research being done to address them.